BPC-157 in Preclinical Tissue Repair Models: A Literature Overview

Some of the earliest and most replicated findings with BPC-157 involve tendon-to-bone healing in rodent models. Sikiric and colleagues demonstrated accelerated Achilles tendon repair in rats, with histological evidence of improved collagen organization and increased tendon-to-bone junction strength compared to vehicle-treated controls.

Subsequent work by Chang et al. (2011) showed that BPC-157 upregulates the expression of early growth response protein 1 (EGR-1) and tenascin-C in tenocytes, suggesting a role in the early fibroblastic phase of tendon repair. The peptide also appears to promote VEGF expression, supporting the angiogenic component of healing.

BPC-157 was originally isolated in the context of gastric cytoprotection research. Multiple rodent studies have demonstrated protection against ethanol-, indomethacin-, and stress-induced gastric lesions. The proposed mechanism involves upregulation of nitric oxide (NO) synthase and modulation of the NO/cGMP pathway, which promotes mucosal blood flow and epithelial restitution.

A 2012 study by Sikiric et al. demonstrated that BPC-157 counteracted the ulcerogenic effects of NSAIDs in rats, with effects observed at doses as low as 10 ng/kg administered intraperitoneally — suggesting high potency relative to molecular weight.

Peripheral nerve injury models have shown that BPC-157 accelerates functional recovery following crush injury and transection in rats. Gjurasin et al. (2010) reported improved motor function scores and histological evidence of axonal regeneration in sciatic nerve crush models, with BPC-157-treated animals recovering grip strength significantly faster than controls.

The proposed mechanism involves upregulation of growth factors including NGF and GDNF at the injury site, as well as modulation of the inflammatory microenvironment to favor a pro-regenerative phenotype.

BPC-157 does not appear to act through a single receptor; rather, the literature suggests pleiotropic activity involving the NO system, growth factor signaling (EGR-1, VEGF, NGF), and modulation of the dopaminergic and serotonergic systems. Its stability in gastric juice — unlike most peptides — may contribute to its activity in GI models.

It is important to note that all published studies to date are preclinical (rodent models). No peer-reviewed randomized controlled trials in humans have been published as of 2026. BPC-157 remains a research compound only.